Moderna, Inc. (NASDAQ:MRNA)’s stock price dropped 5% on Monday after an insider sold shares in the company. The stock traded as low as $408.50 and last traded at $408.50. Approximately 410,487 shares were traded during trading, a decline of 97% from the average daily volume of 13,519,586 shares. The stock had previously closed at $430.14.
Specifically, President Stephen Hoge sold 20,000 shares of the company’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $447.41, for a total transaction of $8,948,200.00. Following the completion of the transaction, the president now directly owns 1,614,597 shares in the company, valued at $722,386,843.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tal Zvi Zaks sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 30th. The stock was sold at an average price of $237.00, for a total transaction of $1,185,000.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $1,185,000. The disclosure for this sale can be found here. Insiders sold a total of 329,000 shares of company stock worth $117,458,920 over the last ninety days. Insiders own 19.40% of the company’s stock.
Several research firms have recently commented on MRNA. Chardan Capital reissued a “buy” rating on shares of Moderna in a research note on Wednesday, July 7th. Piper Sandler lowered shares of Moderna from an “overweight” rating to a “neutral” rating in a research note on Friday, August 6th. Argus raised their target price on shares of Moderna from $200.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, June 24th. Morgan Stanley raised their target price on shares of Moderna from $190.00 to $337.00 and gave the company an “equal weight” rating in a report on Tuesday, September 7th. Finally, Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Thursday, August 5th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and an average price target of $205.21.
Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 5th. The company reported $6.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.01 by $0.45. The firm had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Moderna had a return on equity of 88.13% and a net margin of 49.79%. Moderna’s quarterly revenue was up 6457.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.31) EPS. As a group, equities analysts predict that Moderna, Inc. will post 29.13 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in MRNA. Capital Analysts LLC acquired a new stake in shares of Moderna during the 1st quarter valued at approximately $26,000. Evermay Wealth Management LLC acquired a new stake in Moderna in the second quarter worth $28,000. Winch Advisory Services LLC increased its position in Moderna by 1,785.7% in the second quarter. Winch Advisory Services LLC now owns 132 shares of the company’s stock worth $31,000 after buying an additional 125 shares during the period. Certified Advisory Corp acquired a new stake in Moderna in the first quarter worth $33,000. Finally, Elmwood Wealth Management Inc. acquired a new stake in Moderna in the first quarter worth $33,000. Institutional investors own 55.89% of the company’s stock.
About Moderna (NASDAQ:MRNA)
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Recommended Story: Commodities
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.